These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12225725)

  • 1. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
    Wong M; Staszewsky L; Latini R; Barlera S; Volpi A; Chiang YT; Benza RL; Gottlieb SO; Kleemann TD; Rosconi F; Vandervoort PM; Cohn JN;
    J Am Coll Cardiol; 2002 Sep; 40(5):970-5. PubMed ID: 12225725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
    Wong M; Staszewsky L; Latini R; Barlera S; Glazer R; Aknay N; Hester A; Anand I; Cohn JN
    J Am Coll Cardiol; 2004 Jun; 43(11):2022-7. PubMed ID: 15172407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT).
    Wong M; Staszewsky L; Volpi A; Latini R; Barlera S; Höglund C
    J Am Soc Echocardiogr; 2002 Apr; 15(4):293-301. PubMed ID: 11944005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
    Cohn JN; Tognoni G; Glazer R; Spormann D
    Eur J Heart Fail; 2000 Dec; 2(4):439-46. PubMed ID: 11113722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valsartan for the treatment of heart failure.
    Latini R; Masson S; Staszewsky L; Maggioni AP
    Expert Opin Pharmacother; 2004 Jan; 5(1):181-93. PubMed ID: 14680446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P; Tognoni G; Cohn JN
    J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R; Masson S; Anand I; Judd D; Maggioni AP; Chiang YT; Bevilacqua M; Salio M; Cardano P; Dunselman PH; Holwerda NJ; Tognoni G; Cohn JN;
    Circulation; 2002 Nov; 106(19):2454-8. PubMed ID: 12417542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical study of the month. Effects of valsartan in chronic heart failure: the VAL-HeFT study].
    Piérard L
    Rev Med Liege; 2002 Jan; 57(1):57-9. PubMed ID: 11899501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
    Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
    Kim S; Yoshiyama M; Izumi Y; Kawano H; Kimoto M; Zhan Y; Iwao H
    Circulation; 2001 Jan; 103(1):148-54. PubMed ID: 11136700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB; Schlosshan D; Williams SG
    Int J Clin Pract; 2004 Feb; 58(2):184-91. PubMed ID: 15055867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG; Rector TS; Anand IS; Cohn JN
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN; Tognoni G;
    N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of recent clinical trials for heart failure performance measures.
    Executive Council Of The Heart Failure Society Of America
    J Card Fail; 2004 Feb; 10(1):4-5. PubMed ID: 14966767
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of angiotensin II type 1 receptor antagonist valsartan on cardiac remodeling and left ventricular function in patients with acute ST-elevation myocardial infarction.
    Ovricenco E; Sinescu C; Dinescu S
    J Med Life; 2008; 1(3):323-33. PubMed ID: 20108509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study].
    Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN
    Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.